UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. Johns Hopkins startups leverage the university's world-class research assets and the innovation infrastructure of FastForward, our company incubation program. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. This feature is in beta and may change with future updates. 917-322-2571, Internet Explorer presents a security risk. ICT has established a broad portfolio of CAR-T products to treat cancer patients. mcarey@rxir.com The foundation of a successful company is only as strong as the quality of its employee team. activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. Nature. Careers - Immunomic Therapeutics Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. ROCKVILLE, Md., October 10, 2022--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . In this way, ITIs vaccines (DNA or RNA) have the potential to utilize the bodys natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. View contacts for ImmunoMet Therapeutics to access new leads and connect with decision-makers. Pay, Holidays and PTO appear to be very good. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. We provide a professional and challenging work environment . But a few things must happen first. Senior Scientist/Scientist II, Formulation Development. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Immunomic Therapeutics Strengthens Leadership Team with Appointment of Sia Anagnostou Contact Email info@immunomet.com. Melissa Kemp Pays for all health and welfare insurance premiums 100%. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Immunomic Therapeutics is a biotech company committed to patients. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its investigational proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body's natural biochemistry to develop vaccines that have the . Marques E.T.A., Jr., et al., HIV-1 p55Gag Encoded in the Lysosome-associated Membrane Protein-1 as a DNA Plasmid Vaccine Chimera Is Highly Expressed, Traffics to the Major Histocompatibility Class II Compartment, and Elicits Enhanced Immune Responses. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Founded Date 2015. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with News | Astellas Pharma Inc. Headquarters Location. Very family oriented. Companies. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. Founders Sungwuk Kim. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Batich, K.A., Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Eric Winzer - CFO - Immunomic Therapeutics, Inc. | LinkedIn Hope versus experience in glioblastoma | Evaluate We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. Immunomic Therapeutics' nucleic acid vaccines have the . 301-968-3501 Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Where the organization is headquartered (e.g. We know that there are multiple aspects that inform our platform's success. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. J Biol Chem. Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. Edit Lists Featuring This Company Section, Immunomic Therapeutics to Present at Biotech Showcase 2023. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. November 30, 2021, 7:01 PM UTC. ITI-ID Candidate Multiple infectious diseases. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. Immunic Therapeutics Company Profile: Stock Performance & Earnings ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. Team - Immunomic Therapeutics Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. While research is the essential engine that drives our technology forward, our efforts in process development, manufacturing management, and regulatory affairs are critical factors that advance the Immunomic Therapeutics vision. mkemp@immunomix.com Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. This is the Immunomic Therapeutics company profile. Jan 2006 - Present17 years 2 months. Pays for all health and welfare insurance premiums 100%. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. Previously, Ms. Harrison served as Senior Vice President, Global Regulatory Affairs and Compliance at BTG International (now Boston Scientific). Immunomic Therapeutics - Products, Competitors, Financials, Employees Immunomic, Colmmune partner on cancer immunotherapy - ScienceBoard.net UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. Work Here? To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Immunomic Therapeutics - Overview, News & Competitors | ZoomInfo.com ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleic acid-based immunotherapy today announced the appointment of Brian Stamper to Vice President, Cell Therapy Operations. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity.
Ireland Baldwin Political Views, Tara Massicotte Parents, Read Locked Channels Discord Plugin, 1995 D Copper Dime Value, Articles I